(Q38366396)

2 September 2017

1 reference

title

Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence (English)

1 reference

2 September 2017

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727651%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Christina Wefers

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727651%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Laurens J Lambert

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727651%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Stanleyson V Hato

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727651%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

English

0 references

publication date

26 February 2015

1 reference

2 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727651%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

137

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727651%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727651%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

335-342

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727651%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Cancer immunotherapy comes of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Immunogenic cell death in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

STATing the importance of immune modulation by platinum chemotherapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Targeting natural killer cells and natural killer T cells in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

T(H)17 cells in tumour immunity and immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Foxp3 expression in human cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Is FOXP3 a bona fide marker for human regulatory T cells?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Tumor-associated macrophages contribute to tumor progression in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Macrophages, innate immunity and cancer: balance, tolerance, and diversity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Involvement of M2‐polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Adoptive immunotherapy for cancer: harnessing the T cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Cancer Stem Cells: From Bench to Bedside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

The cancer stem cell gamble.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Functional OCT4-specific CD4(+) and CD8(+) T cells in healthy controls and ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.02.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2015.02.019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727651%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference